Giuseppina Roscigno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4961898/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget, 2017, 8, 19592-19608.	1.8	267
2	The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. International Journal of Molecular Sciences, 2019, 20, 4687.	4.1	111
3	MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget, 2016, 7, 580-592.	1.8	84
4	miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells. PLoS ONE, 2013, 8, e74466.	2.5	84
5	MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget, 2017, 8, 19507-19521.	1.8	63
6	Highly Homogeneous Biotinylated Carbon Nanodots: Red-Emitting Nanoheaters as Theranostic Agents toward Precision Cancer Medicine. ACS Applied Materials & Interfaces, 2019, 11, 19854-19866.	8.0	61
7	Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL. Molecular Therapy - Nucleic Acids, 2016, 5, e289.	5.1	60
8	Direct determination of small RNAs using a biotinylated polythiophene impedimetric genosensor. Biosensors and Bioelectronics, 2017, 87, 1012-1019.	10.1	51
9	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 2018, 13, 334-346.	5.1	43
10	Neutrophil Gelatinase–Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2015, 8, e002673.	3.9	38
11	RYK promotes the stemness of glioblastoma cells via the WNT/β-catenin pathway. Oncotarget, 2017, 8, 13476-13487.	1.8	38
12	miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of <i>NRAS</i> . Oncotarget, 2016, 7, 19531-19547.	1.8	36
13	The Discovery of RNA Aptamers that Selectively Bind Glioblastoma Stem Cells. Molecular Therapy - Nucleic Acids, 2019, 18, 99-109.	5.1	33
14	Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer. Cancers, 2019, 11, 1521.	3.7	29
15	Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells. Molecular Therapy - Nucleic Acids, 2020, 20, 176-185.	5.1	29
16	Identification of a novel RNA aptamer that selectively targets breast cancer exosomes. Molecular Therapy - Nucleic Acids, 2021, 23, 982-994.	5.1	29
17	Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer. Molecular Therapy - Nucleic Acids, 2022, 28, 17-31.	5.1	25
18	Urinary Dickkopf-3 and Contrast-Associated Kidney Damage. Journal of the American College of Cardiology, 2021, 77, 2667-2676.	2.8	18

#	Article	IF	CITATIONS
19	A dominant mutation etiologic for human trichoâ€dentoâ€osseous syndrome impairs the ability of DLX3 to downregulate ΔNp63α. Journal of Cellular Physiology, 2011, 226, 2189-2197.	4.1	14
20	Modulating the Crosstalk between the Tumor and the Microenvironment Using SiRNA: A Flexible Strategy for Breast Cancer Treatment. Cancers, 2020, 12, 3744.	3.7	13
21	miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. International Journal of Molecular Sciences, 2020, 21, 2313.	4.1	13
22	miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer. Cancer Gene Therapy, 2021, 28, 413-426.	4.6	13
23	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. International Journal of Cardiology, 2017, 244, 112-118.	1.7	10
24	Comparative Proteomic Profiling of Secreted Extracellular Vesicles from Breast Fibroadenoma and Malignant Lesions: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 3989.	4.1	6